The InflaRx technology
InflaRx develops highly specific monoclonal antibodies targeting activation products of the complement system. InflaRx has made new break through discoveries in the area of anti-C5a antibody generation, resulting in a new class of antibodies with exceptional blocking activities while being highly selective. The InflaRx anti-complement technology is the basis for a pipeline of new antibodies addressing a broad variety of inflammatory diseases.
ANTI C5A Technology
The InflaRx team has discovered and globally patented a new conformational epitope within the C5a molecule allowing for generation of highly selective and potent blocking monoclonal antibodies directed against this target. These antibodies are able to fulfill the major three requirements determined by InflaRx for generation of suitable drug candidates:
1) delivering a complete immunological blockade / inhibition of C5a induced effects - this is important because of the abundant presence and generation capacity of C5a in the human body. Antibodies not achieving this requirement will likely leave a "signaling gap" for C5a, which in any disease setting will cause strong pro-inflammatory effects, thus limiting the ability to silence this signaling axis and to achieve the desired therapeutic effect.
2) being fully selective = leaving formation of the membrane attack complex intact - this is important because C5 blocking molecules that block the ability for MAC formation in the blood, bear the risk of life threatening infections caused by encapsulated bacteria such as meningococci and others for patients being treated with them. In any disease in which C5a plays a contributing or damaging role and in any life-threatening acute infectious disease, leaving MAC formation intact in a targeted blocking approach directed against C5a translates into an improved safety profile for the patient. Thus, specificity is an important consideration.
3) binding with high affinity to C5a – this is important because C5a, once generated, is believed to interact rapidly with its receptors which are abundantly present on practically every cell type in the human body and which can even be up-regulated in various disease settings. Thus, a suitable anti-C5a antibody must be capable of interfering such interaction rapidly, capturing C5a before it can interact with its receptors and cause signaling events that translate in the well researched pro-inflammatory effects
InflaRx´ lead drug candidate IFX-1 is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical phase II development.
In preclinical studies in non-human primates, proof of concept was demonstrated for the extraordinary anti-inflammatory and tissue saving potential of IFX-1. IFX-1 has been proven safe and well tolerated in a double blind placebo controlled dose escalation Phase I study in healthy human volunteers. In a first clinical phase IIA multi-center placebo-controlled dose escalation study in patients suffering from early septic organ dysfunction, biological proof of concept could be established, demonstrating its unique C5a blocking ability as well as selectivity (leaving MAC formation intact).
IFX-1 holds large potential in various inflammatory disease indications and is currently being developed in 4 independent indications.
IFX-2 is a follow on project to IFX-1, in preclinical development. IFX-2 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered pharmacokinetic properties.
IFX-2 is developed to target chronic inflammatory diseases with high unmet medical need. Recent scientific publications suggest a fundamental role of the complement factor C5a for disturbance of the T-cell homeostasis thereby contributing to mechanisms involved in chronic and auto-immune inflammatory diseases. Therapies blocking the C5a / C5aR axis are therefore believed to induce regulatory T-cell generation and decrease Th17- and Th1 type responses. Thus a therapeutic anti-C5a approach offers applicability within a large variety of T-cell driven inflammatory diseases.
IFX-3 is a first bi-specific monoclonal antibody in InflaRx` R&D pipeline in early stage development. This first-of-its kind molecule was designed to simultaneously block an important factor of the complement pathway and another key inflammatory mediator. IFX-3 is predicted to deliver key advantages in selected sub-acute and chronic inflammatory diseases with special focus on auto-immune indications.